Valuation: Santhera Pharmaceuticals Holding AG

Market Cap 242M 298M 257M 220M 414M 28.49B 420M 2.83B 1.11B 14.27B 1.12B 1.09B 47.42B P/E 2026 *
-
P/E 2027 * -
Enterprise Value 270M 332M 287M 245M 461M 31.76B 468M 3.16B 1.23B 15.9B 1.25B 1.22B 52.85B EV / Sales 2026 *
2.85x
EV / Sales 2027 * 2.28x
Free-Float
81.52%
Yield 2026 *
-
Yield 2027 * -
1 day-0.88%
1 week+0.13%
Current month+12.01%
1 month+1.15%
3 months-7.79%
6 months-2.70%
Current year+25.87%
1 week 15.68
Extreme 15.68
16.9
1 month 13.86
Extreme 13.86
16.9
Current year 11.7
Extreme 11.7
18.84
1 year 9.38
Extreme 9.38
18.84
3 years 7.14
Extreme 7.14
18.84
5 years 5
Extreme 5
26.6
10 years 5
Extreme 5
820
Manager TitleAgeSince
Chief Executive Officer 50 15/07/2026
Director of Finance/CFO 51 24/02/2025
Chief Operating Officer 55 01/09/2022
Director TitleAgeSince
Chairman 64 30/06/2022
Director/Board Member 58 04/04/2017
Director/Board Member 47 27/06/2023
Date Insider Type Main position Quantity % Market Cap.
1/22/24 A Buy 30,228 0.2396%
7/6/23 A Buy 2,000 0.0016%
1/11/22 A Buy 30,000 0.0549%
Change 5-day change 1-year change 3-year change Capi.($)
-0.88%+0.13%+15.94%+92.24% 298M
+0.21%+5.65%+61.31%+25.01% 335B
-2.29%-5.12%+21.64%-15.21% 68.61B
-2.00%-4.33%+46.66%+124.13% 11.2B
-1.26%+1.30%-2.03%-4.67% 8.49B
-0.34%+2.22%-13.22%-8.59% 4.84B
+1.45%+3.85%-26.84%+16.87% 4.42B
+0.32%-2.16%+0.82%+45.93% 4.28B
+2.57%+1.51%+13.28%+51.88% 2.81B
-1.59%-2.84%-4.94%-3.92% 2.19B
Average -0.38%-0.06%+11.26%+32.37% 44.23B
Weighted average by Cap. -0.25%+3.43%+50.63%+20.54%

Financials

2026 *2027 *
Net sales 94.7M 117M 101M 86.13M 162M 11.16B 165M 1.11B 434M 5.59B 438M 429M 18.57B 116M 142M 123M 105M 198M 13.61B 201M 1.35B 529M 6.82B 535M 523M 22.66B
Net income - -
Net Debt 27.7M 34.13M 29.48M 25.19M 47.36M 3.26B 48.14M 325M 127M 1.63B 128M 125M 5.43B 21.4M 26.37M 22.77M 19.46M 36.59M 2.52B 37.19M 251M 98.04M 1.26B 99M 96.85M 4.2B
Logo Santhera Pharmaceuticals Holding AG
Santhera Pharmaceuticals Holding AG (Santhera) is a Switzerland-based company engaged in the pharmaceutical sector. The Company operates through one business segment, which is the research, development and commercialization of pharmaceutical products for the treatment of neuromuscular and mitochondrial diseases, such as Duchenne muscular dystrophy (DMD) and cystic fibrosis (CF). The Company focuses also on development of gene therapy for the treatment of LAMA2 (Laminin Subunit Alpha 2) deficient congenital muscular dystrophy (CMD). Santhera operates through its wholly owned subsidiaries: Santhera Pharmaceuticals (Schweiz) AG, Liestal, Santhera Pharmaceuticals (USA) Inc, Santhera Pharmaceuticals (Canada) Inc, Santhera Pharmaceutical (Deutschland) GmbH and Oy Santhera Pharmaceuticals (Finland) Ltd.
Employees
94
Date Price Change Volume
14/08/26 CHF 15.86 -0.88% 71,891
13/08/26 CHF 16.00 +0.76% 30,851
12/08/26 CHF 15.88 -1.61% 74,708
11/08/26 CHF 16.14 -1.59% 114,540
10/08/26 CHF 16.40 +3.54% 123,290
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
15.86CHF
Average target price
27.50CHF
Spread / Average Target
+73.39%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. SANN Stock